Compared to Estimates, Evolent Health (EVH) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Evolent Health (EVH) reported revenue of $652.52 million, up 46.9% over the same period last year. EPS came in at $0.02, compared to -$0.10 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $611.13 million, representing a surprise of +6.77%. The company delivered an EPS surprise of +300%, with the consensus EPS estimate being -$0.01.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Evolent Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Average PMPM Fees / Revenue per Case - Performance Suite: $24.05 compared to the $20.99 average estimate based on two analysts.
• Average PMPM Fees / Revenue per Case - Specialty Technology and Services Suite: $0.34 versus $0.35 estimated by two analysts on average.
• Average PMPM Fees / Revenue per Case - Administrative Services: $13.46 versus $15.03 estimated by two analysts on average.
• Average Lives on Platform / Cases - Cases: 12 thousand versus 11.1 thousand estimated by two analysts on average.
• Average Lives on Platform / Cases - Performance Suite: 6.72 million versus 6.86 million estimated by two analysts on average.
• Average Lives on Platform / Cases - Specialty Technology and Services Suite: 75.64 million compared to the 75.28 million average estimate based on two analysts.
• Average Lives on Platform / Cases - Administrative Services: 1.19 million versus the two-analyst average estimate of 1.12 million.
• Average PMPM Fees / Revenue per Case - Cases: $3,608.00 compared to the $3,795.59 average estimate based on two analysts.
• Total Revenue by product type- Performance Suite: $484.5 million compared to the $441.89 million average estimate based on three analysts. The reported number represents a change of +80.8% year over year.
• Total Revenue by product type- Cases: $41.87 million versus $41.09 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7% change.
• Total Revenue by product type- Administrative Services: $47.99 million versus the three-analyst average estimate of $49.59 million. The reported number represents a year-over-year change of -14.1%.
• Total Revenue by product type- Specialty Technology and Services Suite: $78.16 million versus $80.06 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -4% change.

View all Key Company Metrics for Evolent Health here>>>

Shares of Evolent Health have returned -45% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Evolent Health, Inc (EVH): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research